^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Padcev (enfortumab vedotin-ejfv) (Microtubule inhibitor, Nectin-4-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV-103 cohort K.
Published date:
02/13/2023
Excerpt:
The cORR analysis was performed in prespecified subgroups including age, ECOG PS, liver metastasis, PD-L1 expression status...cORRs across key subgroups for both EV+P and EV monotherapy are shown in the table….EV+P showed promising cORR in 1L cisplatin-ineligible pts w/ la/mUC; activity was consistently observed across a range of pre-specified subgroups including those with poor prognosis....cORR by Subgroup, % (95% CI)...PD-L1 expression CPS <10...61.4 (45.5, 75.6)...
DOI:
10.1200/JCO.2023.41.6_suppl.499
Trial ID:
